Does Anthem (Elevance Health) Cover Zetia (Ezetimibe)?

What Ezetimibe Is and Why Insurers Scrutinize It

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border, reducing dietary and biliary cholesterol absorption by roughly 54% [1]. That single mechanism lowers LDL-C by 18-25% as monotherapy and adds 20-25 percentage points on top of statin therapy [2]. The FDA granted initial approval in October 2002 under the brand name Zetia for primary hyperlipidemia and mixed hyperlipidemia [3].

Because a high-quality generic version has been available since 2017, insurers including Anthem (Elevance Health) treat the branded Zetia with skepticism. The generic is therapeutically identical, so payers often require patients to use it instead of the brand. When a physician writes specifically for brand-name Zetia without a "dispense as written" note on a plan that covers generics, the claim may deny outright.

The cardiovascular outcome trial IMPROVE-IT (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of major adverse cardiovascular events by 6.4% relative to simvastatin alone (absolute risk reduction 2.0 percentage points) at a median follow-up of 6 years [4]. The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline cites this trial as establishing ezetimibe's role as the preferred nonstatin add-on in very-high-risk patients with insufficient LDL-C lowering on maximally tolerated statin therapy [5].

Those guidelines state directly: "In patients with clinical ASCVD on maximally tolerated statin therapy whose LDL-C remains 70 mg/dL or higher, it is reasonable to add ezetimibe therapy." [5] Anthem's medical policy documents echo this framework closely, which is precisely why prior authorization forms ask about LDL-C levels and statin history.

Anthem's Current Formulary Position for Zetia and Generic Ezetimibe

Anthem operates multiple formulary lists across its commercial, Medicare Advantage, and Medicaid product lines. Positions differ by state and plan design. On the most widely used Anthem Enhanced Value Formulary as of 2025, generic ezetimibe 10 mg sits at Tier 2 (generic), and brand-name Zetia sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific plan document.

Tier 2 copays typically run $15-40 per 30-day fill. Tier 3 copays run $45-75. Tier 4 copays, where applicable, can reach $90-120 before deductible. Patients enrolled in high-deductible health plans (HDHPs) pay the full negotiated rate until the deductible clears, which may be $2,500 or more annually.

Anthem's Pharmacy and Therapeutics (P&T) Committee reviews the formulary quarterly. The most current formulary specific to any given plan appears in the Summary of Benefits and Coverage (SBC) document on the Anthem member portal at anthem.com. Physicians should pull the actual formulary document rather than relying on memory, because Anthem's 2024-2025 formulary cycle moved generic ezetimibe to Tier 2 on some plans where it had previously been Tier 3 [6].

For Medicaid managed care plans administered by Anthem affiliate companies (such as Anthem Blue Cross of California's Medi-Cal line), ezetimibe is covered on the state's preferred drug list with fewer PA restrictions. Medicare Advantage formularies are Part D-regulated and vary by plan; the Anthem Medicare Advantage drug formulary search tool at anthem.com confirms tier status by entering the drug name and zip code.

Prior Authorization Criteria for Zetia on Anthem Plans

Prior authorization is required on most Anthem commercial plans before ezetimibe (brand or generic) will be covered. The documentation Anthem's pharmacy team typically requests includes the following elements.

First, a confirmed diagnosis of primary hypercholesterolemia or mixed dyslipidemia consistent with ICD-10 codes E78.00, E78.01, or E78.2 [7]. Second, a baseline fasting lipid panel showing LDL-C at or above the threshold specified by the prescribing physician's risk category assessment. Third, documentation that the patient has tried and tolerated (or has a documented contraindication to) at least one statin at a moderate-to-high intensity dose for a minimum of 90 days [5].

The 90-day statin trial is the most common sticking point. Physicians sometimes submit PA requests after only 30 days of statin therapy, which Anthem reviewers reject as insufficient. The ACC/AHA guideline defines maximally tolerated statin therapy as the highest statin dose the patient can take without adverse effects, not simply any statin dose [5]. Anthem's clinical reviewers apply that standard.

Statin intolerance is an accepted alternative pathway. If the patient experienced myalgia with a creatine kinase (CK) elevation greater than 4 times the upper limit of normal on two separate statins, or rhabdomyolysis, Anthem may approve ezetimibe as first-line nonstatin therapy. The prescriber must submit the CK lab values and documentation of the specific statins and doses tried [8].

PA approvals, once granted, are typically valid for 12 months. Anthem's standard PA review timeline is 72 hours for non-urgent cases and 24 hours for urgent cases, per the federal Consolidated Appropriations Act of 2021 and CMS guidance on Medicare Advantage [9].

Step Therapy Requirements Before Ezetimibe

Step therapy (also called "fail-first" requirements) means Anthem requires documented failure of a preferred lower-tier drug before covering a higher-tier option. For ezetimibe, the step is a statin, not a different lipid-lowering agent.

Specifically, Anthem's step therapy protocols for hyperlipidemia adjunctive therapy require that patients have tried at least one high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) or a moderate-intensity statin at maximum tolerated dose before ezetimibe will be approved as an add-on agent [5]. This aligns with ACC/AHA 2018 guidance that positions ezetimibe as a second-line add-on rather than a first-line monotherapy in most risk categories.

If a patient is already on a PCSK9 inhibitor (evolocumab or alirocumab) and still not at LDL-C goal, ezetimibe may be added without re-running step therapy for ezetimibe specifically, because the statin trial already on file satisfies the statin step. The physician should note this in the PA submission to avoid a redundant denial.

State-level step therapy override laws affect Anthem plans. As of 2025, 30 states plus the District of Columbia have enacted step therapy reform legislation requiring insurers to grant a step therapy override within specified timelines when the standard therapy is contraindicated, clinically inappropriate, or the patient previously failed it [10]. Patients in those states whose physicians submit complete clinical documentation have a legally protected pathway to bypass the statin step if appropriate.

How to Submit a Prior Authorization Request for Ezetimibe

The prescribing physician or their staff submits PA requests through Anthem's CareCore or AIM Specialty Health portals, by fax to the number on the member's ID card, or through the NaviNet provider portal. Electronic submissions through these portals generate a tracking number immediately and are preferable to fax.

The PA request should include the following documentation in a single organized submission. The current lipid panel (dated within 90 days) with LDL-C value clearly highlighted. A written note or letter summarizing the statin(s) tried, dose, duration, and reason for discontinuation or reason for adding ezetimibe. The ICD-10 diagnosis code. Any cardiovascular risk calculator output (such as the ACC/AHA Pooled Cohort Equations score) that establishes 10-year ASCVD risk [5].

Complete submissions reduce the back-and-forth that extends approval timelines. Anthem's utilization management team may call the prescribing office to request missing information, which can add 3-5 business days to the review.

Appealing an Anthem Denial of Zetia Coverage

Anthem denials arrive by mail and specify the reason for denial and the appeal deadline, which is typically 180 days from the denial date for internal appeals on commercial plans [11]. Two formal appeal levels exist within Anthem before external review becomes available.

Level 1 internal appeal. The physician or patient submits a written appeal to Anthem's Appeals and Grievances department. The appeal packet should include a physician letter of medical necessity, the most recent lipid panel, documentation of statin intolerance or failure, and any relevant published guidelines or trial data. Attaching the IMPROVE-IT publication or the ACC/AHA 2018 Cholesterol Guideline's ezetimibe recommendation section directly is good practice [4, 5]. Anthem must respond within 30 days for pre-service appeals or 60 days for post-service appeals on commercial plans [11].

Level 2 internal appeal. If Level 1 fails, the case goes to a different Anthem medical reviewer. Response timelines mirror Level 1.

External Independent Review. After exhausting internal appeals, patients on fully insured commercial plans can request review by a state-assigned Independent Review Organization (IRO). The IRO's decision is legally binding on Anthem in most states. For self-funded (ERISA) employer plans, the external review pathway is governed by the plan's Summary Plan Description and federal ERISA rules rather than state insurance law, which limits some protections [12].

The HealthRX clinical team uses the following structured appeal framework for ezetimibe denials:

1. Pull the Explanation of Benefits (EOB) and identify the exact denial reason code.
2. Match the denial reason to the specific ACC/AHA guideline language or IMPROVE-IT data that contradicts it.
3. Have the prescribing physician write a one-page letter addressing that exact reason code, not a generic medical necessity letter.
4. Submit the letter, the lipid panel, the statin trial documentation, and the relevant guideline excerpt as a single PDF.
5. Request an expedited peer-to-peer review call with the Anthem medical director within 5 business days of the denial.

Peer-to-peer calls, where the prescribing physician speaks directly with the Anthem medical director who denied the claim, overturn denials in a meaningful proportion of cases. Physicians should request this call proactively rather than waiting for Anthem to offer it.

Manufacturer Savings Programs and Cash-Pay Alternatives

Merck's Zetia Savings Card (available at zetia.com) reduces out-of-pocket cost to as low as $5 per month for eligible commercially insured patients, with a maximum benefit of $130 per fill [13]. The card is not valid for patients covered by Medicare, Medicaid, or any government-funded program. Anthem commercial plan members are generally eligible if they meet income or other eligibility criteria specified on the card's terms.

However, using a manufacturer savings card on a drug that requires PA and has not yet been approved may lead to a claim denial at the pharmacy level. The pharmacist will process the brand drug, but if Anthem's PA is still pending or denied, the claim may not adjudicate through insurance at all. In that scenario, the savings card serves as a cash-pay discount rather than a co-pay assistance card.

Generic ezetimibe 10 mg is widely available for $10-20 per 30-day supply at GoodRx-participating pharmacies without any manufacturer card [14]. For patients whose Anthem plan has a high deductible or whose PA is pending, paying cash for generic ezetimibe is often the fastest and cheapest path to starting therapy. The prescribing physician simply writes a prescription for generic ezetimibe 10 mg daily, and the patient fills it at a discount pharmacy using a GoodRx or similar coupon.

Patients who pay cash should understand that those payments typically do not count toward their Anthem deductible or out-of-pocket maximum, depending on plan design. Some Anthem PPO plans allow out-of-network cash payments to count toward the deductible; most HMO plans do not.

Ezetimibe in Special Populations Covered by Anthem Plans

Familial Hypercholesterolemia (FH). Patients with heterozygous FH (HeFH) or homozygous FH (HoFH) often have a stronger PA case because their LDL-C levels are genetically elevated and statin monotherapy is rarely sufficient. The FDA-approved indication for ezetimibe in HoFH (in combination with atorvastatin or simvastatin) provides clear grounds for medical necessity [3]. Anthem's PA form for FH patients should include genetic testing results or clinical diagnostic criteria (Dutch Lipid Clinic Network score or Simon Broome criteria) if available [15].

Statin-intolerant patients. The National Lipid Association defines statin intolerance as the inability to tolerate two or more statins at any dose due to adverse effects [8]. Anthem's PA criteria recognize this pathway. The prescriber's letter should name both statins tried (for example, atorvastatin 20 mg and rosuvastatin 10 mg), the specific adverse effect with supporting labs if applicable, and the dates of each trial.

Pediatric patients. Ezetimibe is FDA-approved for patients 10 years and older with HeFH or HoFH [3]. Anthem pediatric formulary coverage follows similar PA rules, but the statin trial duration requirement may be shorter in younger patients given guideline recommendations for earlier aggressive LDL-C lowering in FH [15].

Post-acute coronary syndrome (ACS). IMPROVE-IT specifically enrolled post-ACS patients and showed that adding ezetimibe to simvastatin 40 mg in patients with LDL-C between 50 and 100 mg/dL reduced 7-year cardiovascular death, major coronary events, and stroke by 6.4% relative risk reduction [4]. Physicians managing post-ACS patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin should include the IMPROVE-IT citation and the ACC/AHA Class IIa recommendation in any PA submission or appeal for this population [5].

Reading Your Anthem Explanation of Benefits for Ezetimibe

When a pharmacy claim for ezetimibe is processed (or denied), Anthem generates an Explanation of Benefits (EOB) document available on the Anthem member portal within 5-7 business days. The EOB lists the claim amount billed, the amount Anthem paid, the member cost share, and, for denials, a reason code.

Common denial reason codes for ezetimibe on Anthem plans include the following. Reason code PA1 or equivalent: prior authorization not obtained before dispensing. Reason code ST1 or equivalent: step therapy requirements not met. Reason code NF1: drug not on formulary (typically applies when brand Zetia is requested and the plan only covers generic).

Understanding the specific code matters because each requires a different appeal strategy. A PA1 denial means the prescriber needs to submit a PA retroactively, which Anthem allows within 30 days in some cases. An ST1 denial means the prescriber must document the statin trial. An NF1 denial for brand Zetia often resolves simply by having the pharmacy substitute generic ezetimibe.

Comparing Ezetimibe to Other Non-Statin Agents on Anthem Formularies

Ezetimibe is not the only non-statin lipid-lowering option Anthem covers, but it is by far the cheapest. PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), reduce LDL-C by 50-60% but carry list prices above $6,000 per month and face even stricter PA requirements on Anthem plans [16]. Bempedoic acid (Nexletol) received FDA approval in 2020 for adults with established ASCVD or FH who require additional LDL-C lowering; Anthem covers it with PA on most commercial formularies as a Tier 3 or Tier 4 agent [17].

Icosapent ethyl (Vascepa) addresses triglycerides rather than LDL-C primarily, so it occupies a different clinical and formulary category. For patients who need LDL-C reduction beyond statin monotherapy, ezetimibe remains the most cost-effective option with the strongest evidence base from IMPROVE-IT.

Ezetimibe's generic availability and low cash price mean that even if Anthem denies coverage, patients are not left without access to the drug. That is not the case for PCSK9 inhibitors, where a denial has real clinical consequences. For this reason, physicians and patients should fight Anthem denials for ezetimibe primarily on principle and cost-sharing grounds, reserving urgent escalation for higher-stakes drugs.

Checking Your Specific Anthem Plan's Formulary

Because Anthem operates across 14 states under various Blue Cross Blue Shield affiliate agreements, and because formulary positions change annually during the October-January plan year transition, the only authoritative source for a specific member's coverage is the formulary document tied to that member's plan ID.

Members can check formulary status at anthem.com by logging in, navigating to "Pharmacy," and using the drug search tool with their plan selected. Physicians can use the NaviNet portal or call Anthem Provider Services at the number on the back of the member's ID card. Pharmacy staff at participating pharmacies can also run a real-time eligibility and formulary check through their dispensing software before the patient pays.

The ACC Foundation's CardioSmart patient resource pages confirm that ezetimibe 10 mg daily is the standard dose for all approved indications, with no dose adjustment required for renal impairment, though caution is advised in moderate-to-severe hepatic impairment [5, 3].